目的  探讨尿N乙酰-β-D氨基葡萄糖苷酶(NAG)、β2微球蛋白在慢性肾病新分期2~4期患者中临床价值。方法  对本院2012年10月至2013年10月肾内科的144例住院患者和54例健康体检者的尿NAG、β2微球蛋白和其他肾功能指标进行检测分析，采用MDRD公式进行肾小球滤过率计算。结果  慢性肾病组尿NAG、β2微球蛋白水平明显高于健康对照组，差异有统计学意义(P<0.01)。2~4期慢性肾病患者中尿α1微球蛋白、β2微球蛋白结果呈明显升高趋势，其差异有统计学意义。尿NAG、β2微球蛋白在3a和3b期中结果有明显差异，3a期尿NAG (35.3±12.4 mg/dL)、3b期尿NAG (45.4±11.5 mg/dL)；3a期尿β2微球蛋白 (0.45±0.35 mg/dL)、3b期β2微球蛋白(1.20±0.88 mg/dL)。相关分析显示，尿NAG、β2微球蛋白与肌酐呈显著正相关，与eGFR呈显著负相关。结论  尿NAG、β2微球蛋白是用于评价慢性肾脏疾病肾功能较好的实验室指标。

Objective To explore the value of the urine N-acetyl-beta-D-glucosaminidase and β2- microglobumin in diagnosis of patients with stage 2-4 chronic kidney disease. Methods Urine N-acetyl-beta-D-glucosaminidase and β2- microglobumin in 144 patients with chronic kidney disease and 50 healthy controls were analyzed. The eGFR was calculated using the modified Modification of Diet in Renal Disease (MDRD) equation. Results There were statistical significance between the patients with chronic kidney disease group and control group with urine N-acetyl-beta-D-glucosaminidase and β2- microglobumin. The level of the urine N-acetyl-beta-D-glucosaminidase and β2- microglobumin were increased in the chronic kidney disease stage 2-4. The urine N-acetyl-beta-D-glucosaminidase levels were 35.3±12.4 mg/dL in stage 3a and 45.4±11.5 mg/dL in stage 3b. The urine β2- microglobumin levels were 0.45±0.35 mg/dL in stage 3a and 1.20±0.88 mg/dL in stage 3b. On the Pearson’s analysis, the urine N-acetyl-beta-D-glucosaminidase and β2- microglobumin were found to be positively correlated to creatinine and negatively correlated to eGFR. Conclusion The urine N-acetyl-beta-D-glucosaminidase and β2- microglobumin might be useful laboratory markers to assess the renal damage of the chronic kidney disease.